Shandong Boan Biotechnology Co., Ltd clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 0 with minor changes only.

1. Notable

   BA1301 in Advanced Solid Tumors

   Primary completion pushed from Jun 30, 2026 to Jun 30, 2027

   Also in this update: Study completion pushed from Dec 31, 2026 to Jun 30, 2027

   Shandong Boan Biotechnology Co., Ltd·Phase 1· NCT06927349· Registry history of NCT06927349 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

2. Notable

   BA1302 · Advanced Solid Tumors

   Primary completion pushed from Dec 31, 2025 to Dec 31, 2027

   Also in this update: Study completion pushed from Dec 30, 2026 to Dec 31, 2027

   Shandong Boan Biotechnology Co., Ltd·Phase 1· NCT06596915· Registry history of NCT06596915 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

3. Notable

   LY01015 and Opdivo® Combined Respectively With Chemotherapy in…LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

   Primary completion date changed from estimate of Jun 2025 to May 17, 2026

   Also in this update: Enrollment closed, study ongoing; Study completion moved earlier from Dec 2026 to Oct 30, 2026

   Shandong Boan Biotechnology Co., Ltd·Phase 3· NCT06022861· Registry history of NCT06022861 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.